KORU MEDICAL SYSTEMS INC (KRMD)
Health Care · Subcutaneous drug delivery and infusion systems · NASDAQ
Koru Medical manufactures FREEDOM Infusion Systems for at-home subcutaneous drug delivery, primarily for immunoglobulin therapy in immunodeficiency diseases, while generating services revenue from pharma partnerships in novel subcutaneous drug development.
What KORU MEDICAL SYSTEMS INC does
Koru Medical develops and manufactures large-volume subcutaneous infusion systems, primarily the FREEDOM Infusion Systems (including syringe drivers, tubing, and needle sets), for drug delivery governed by FDA regulations and international quality standards. The company generates revenue from three streams: domestic and international core product sales of infusion devices for subcutaneous drugs (primarily immunoglobulin treatment for Primary Immunodeficiency Diseases and CIDP), and pharma services including clinical trial feasibility studies and non-recurring engineering services for biopharmaceutical companies developing novel subcutaneous therapies.
Themes: subcutaneous drug delivery, home infusion therapy, immunoglobulin (Ig) therapy, patient-centric care, biopharma partnership services, PIDD treatment, CIDP treatment
Fundamentals
- Price$3.21 as of 2026-08-21 close
- Market cap$148M as of 2026-08-21
- 1-year return-21.9% 2025-08-21 close $4.11 → 2026-08-21 close $3.21
- P/En/a negative earnings
- Net margin-4.0% as of 2026-08-24
- Gross margin+62.4% as of 2026-08-24
- ROE-10.6% as of 2026-08-24
- Debt / equity0.01 as of 2026-08-24
- Revenue growth (YoY)+22.4% as of 2026-08-24
- Revenue CAGR (3y)+13.8% SEC XBRL
- Beta0.36 as of 2026-08-24
- Last reported earnings2026-08-05 SEC EDGAR Form 8-K (Item 2.02)
How KRMD compares in its sector
- net profit marginmiddle range 504 covered Health Care peers, as of 2026-08-24
- operating marginmiddle range 504 covered Health Care peers, as of 2026-08-24
- gross marginmiddle range 384 covered Health Care peers, as of 2026-08-24
- return on equitymiddle range 576 covered Health Care peers, as of 2026-08-24
- 3-year revenue CAGRmiddle range 402 covered Health Care peers
- free cash flow (absolute dollars, latest fiscal year)middle range 493 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
How KORU MEDICAL SYSTEMS INC looks technically
KORU MEDICAL SYSTEMS INC (KRMD) is trading 29.5% below its 200-day average, the long-term trend line — a long-term downtrend. Its 50-day average crossed below its 200-day average about 87 trading days ago — a "death cross", a bearish long-term signal. A strong downtrend is in place — ADX, a 0–100 trend-strength gauge, is 35, with sellers in control. Momentum is beaten down — its 14-day RSI (a 0–100 momentum gauge) is 29, in oversold territory (below 30). It just made a new 20-day low, breaking below its recent trading range. It is trading right at its lowest price of the past year (its 52-week low).
Trend
8
| Distance from the 200-day | it is trading 29.5% below its 200-day average, the long-term trend line — a long-term downtrend | -29.5% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $3.97 | $3.97 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $4.55 | $4.55 |
| Swing structure | each recent peak has been lower than the one before it and each dip deeper — the pattern chart-watchers call a downtrend, which describes where price has already been and not where it goes next | lower highs and lower lows |
| Last swing turn | its last significant turn was a swing low 15 calendar days ago — the swings before that are what the structure reading is measured on | 15 sessions |
| Wave structure | its recent swings can be read as a five-part downward sequence — what Elliott-wave chartists call an impulse — now in the fourth leg, a pullback against that downward direction; the labelling fails if price closes above 3.71. It is one of several labellings that fit, and it describes the swings already printed, not what comes next. The same swings also read as a completed three-part correction. | possible downward five-wave sequence, in wave 4 (one of several readings) |
| Since the 50/200 cross | its 50-day average crossed below its 200-day average about 87 trading days ago — a "death cross", a bearish long-term signal | 87 sessions |
| Trend strength (14-day ADX) | a strong downtrend is in place — ADX, a 0–100 trend-strength gauge, is 35, with sellers in control | 34.5 |
Momentum
3
| 14-day RSI | momentum is beaten down — its 14-day RSI (a 0–100 momentum gauge) is 29, in oversold territory (below 30) | 29.4 |
|---|---|---|
| Position in its 14-day range | it is trading right at the bottom of its 14-day range ($3.20 to $4.35) — its "stochastic" reading is 1 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been slipping within that range over the last few sessions. | 0.9 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, is in negative territory (momentum leaning bearish) | 12 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $6.61 | $6.61 |
|---|---|---|
| From the 52-week high | it is 51.4% below its 52-week high (its highest price of the past year) | -51.4% |
| Above the 52-week low | it is trading right at its lowest price of the past year (its 52-week low) | +0.3% |
| Below the 52-week high | it is 51.4% below its highest point of the past year | 51.4% |
| Since a 20-day breakout | it just made a new 20-day low, breaking below its recent trading range | 1 session |
| Since a 55-day breakout | it just made a new 55-day low, breaking below its recent trading range | 1 session |
| All-time high | its highest closing price on record is $12.84 (set on 2020-04-22) | $12.84 |
| Given back of the 52-week move | over the past year its closes ranged ($3.21 to $6.52), and it has recovered essentially none of its fall from last year’s high — 0% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $5.26 to $5.36. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 0.0% |
| From the all-time high | it is 75.0% below its all-time high | -75.0% |
| Nearest price level | it is trading 4.0% below a resistance level at $3.34 — a price it turned at twice since 2025-03-12, most recently on 2025-05-08. Since 2024-08-21 it has 3 such levels below the current price and 10 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | +4.0% |
| All-time low | its lowest closing price on record is $0.015 (set on 2003-02-03) | $0.015 |
| Above the all-time low | it is 21300.0% above its all-time low | +21,300% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are unusually wide versus its own recent history (wider than about 99% of the past ~6 months) | 99th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $0.1931 between its high and its low — about 6.0% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $0.1931 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $2.92 and $4.43 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $2.92 – $3.67 – $4.43 |
| Typical daily range (% of price) | its price moves about 6.0% in a typical session — more volatile than most companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 6.0% |
| Stretch from the 200-day average | it is trading 7.0 daily ranges below its 200-day average price (29.5% below it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 7.0 daily ranges below its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 1.05× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Candlestick patterns
2
| Since a hammer | 4 sessions ago, after a stretch of decline, it sold off hard during the session and then closed back near its high — a "hammer", the long lower wick showing the drop was bought back before the close | 4 sessions ago |
|---|---|---|
| Since a bearish engulfing | 7 sessions ago it opened above the previous session's close and finished below that session's open — a "bearish engulfing" pair, where one down day more than undid the up day before it | 7 sessions ago |
Price gaps
3
| Gap at the open | it opened on 2026-08-21 at essentially the same price it closed at the session before — no meaningful overnight gap | 0.0% |
|---|---|---|
| Open gap | it gapped 6.7% below the previous close 11 sessions ago and has not traded back through the level it left behind at 4.13 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | -6.7% |
| Gap filled | a 4.6% gap up opened on 2026-07-27 has been "filled" 11 sessions ago — price traded back through the level the gap left behind, and it took 8 sessions to close | 11 sessions ago |
Price streaks
1
| Closing streak | it has closed lower 5 sessions in a row, a -5.59% move over the run — an unbroken run of down days, which describes what has already happened and says nothing about the next session | 5 sessions down |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock lagged the market by 22.7 percentage points (the stock lost 20.3% while the market gained 2.3%) | -22.7% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock lagged the market by 25.6 percentage points (the stock lost 22.5% while the market gained 3.1%) | -25.6% |
| vs market, 6 months | over the past 6 months this stock lagged the market by 43.3 percentage points (the stock lost 32.3% while the market gained 11.1%) | -43.3% |
| vs market, 12 months | over the past 12 months this stock lagged the market by 42.4 percentage points (the stock lost 21.9% while the market gained 20.5%) | -42.4% |
Signal agreement
2
| Bullish technical signals | 2 of the 9 technical signals we can compute for it are currently in a bullish state: its RSI momentum gauge is oversold (a beaten-down reading), near the bottom of its 14-day range (oversold) — these describe past price behaviour, not a forecast | 2 of 9 |
|---|---|---|
| Bearish technical signals | 7 of the 9 technical signals we can compute for it are currently in a bearish state: a strong downtrend, with sellers in control, a "death cross" — its 50-day average is below its 200-day, trading below its 200-day average, a fresh 20-day low, MACD momentum is negative, lagging the market over 6 months, trading below the Ichimoku cloud — these describe past price behaviour, not a forecast | 7 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 25% below the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-07-15 and projected forward over today's price, the side traders read as an established downtrend, with the band above acting as the level that would have to be cleared. The band itself is moderate, spanning 2.5% of the share price. | -24.7% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 27% below the average price paid so far this year, so the typical buyer over that stretch is under water. That average is $4.38 — a volume-weighted average of daily closes over 159 sessions, not a true tick-by-tick VWAP. | -26.8% |
|---|---|---|
| Vs the average paid since it last reported | the price is 6% below the average price paid since it last reported on 2026-08-05 (its 10-Q), so the typical buyer over that stretch is under water. That average is $3.43 — a volume-weighted average of daily closes over 13 sessions, not a true tick-by-tick VWAP. | -6.4% |
Price levels it has turned at before
KRMD last closed at $3.21 on 2026-08-21. Since 2024-08-21 it has turned at 3 prices below its last close and 10 above; the 3 nearest below and the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $3.34 | Resistance | 4.0% above the last close | turned there twice · 2025-03-12 to 2025-05-08 |
| $2.92 | Support | 9.1% below the last close | turned there twice · 2024-10-01 to 2025-07-16 |
| $3.71 | Resistance | 15.7% above the last close | turned there three times · 2025-10-02 to 2026-07-23 |
| $3.82 | Resistance | 19.0% above the last close | turned there four times · 2025-07-09 to 2026-06-22 |
| $2.54 | Support | 20.7% below the last close | turned there twice · 2025-03-14 to 2025-04-15 |
| $2.40 | Support | 25.1% below the last close | turned there twice · 2024-10-08 to 2024-10-28 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a five-part downward sequence — what Elliott-wave chartists call an impulse — now in leg 4 of five, a pullback against that direction.
This labelling fails — stops being a possible reading at all — if it closes above $3.71.
This is one of several labellings that fit the same swings, so treat it as a reading rather than the reading. It was chosen from 2 labellings that survived the rules, counting shorter readings of the same bars.
On past moves of this shape the leg has usually ended somewhere between $3.48 and $3.71 — that is where it has tended to end if the count holds, not a forecast of where the price goes.
Alternate reading: The same swings also read as a completed three-part correction, which fails on a close below $3.21.
This labelling was already in place when we began recording count changes on 2026-08-13, so how long it has stood is not something we can say yet.
Read from daily closes as of 2026-08-21.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading below the 200-day moving average · Oversold (14-day RSI below 30) · Near the 52-week low · Pulled back from the 12-month high · Broke down to a new 20-day low · lagging the market | Learn: moving average · golden cross · adx · rsi · breakout · fifty two week high low
Based on daily closing prices as of 2026-08-21. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingStrong Buy (1.40 mean, 1=Strong Buy…5=Strong Sell) — 5 analysts
- Mean price target$6.60 range $5.00 – $8.00; median $6.00
Analyst estimates, as of 2026-08-22. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for KRMD
- Consensus EPS estimate-$0.02 next reporting period, as of 2026-08-22
Change over time is not available yet: it needs two readings of the same reporting period at least 30 days apart, and we have been recording these estimates since 2026-08-04. An estimate for a DIFFERENT quarter is not a revision, so a reading from before the last report is never compared with one after it.
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Reliance on a limited number of drugs for the majority of revenue, primarily immunoglobulins.","Competitive pressures from alternative drug delivery methods and larger medical device companies.","Uncertainty related to the adoption of the FREEDOM system for novel biopharmaceutical therapies in development."]
What changed in the latest 10-Q
AI-assisted comparison of KRMD's 10-Q filed 2026-05-06 against the prior one filed 2025-11-12.
Management's Discussion & Analysis (MD&A)
- Added:
- Added reference to February 20, 2026 US federal court order regarding tariff refunds and uncertainty about Company's eligibility and timing (newer filing 2026-05-06)
- Added statement that Company has not recorded nor plans to record any benefit related to possible tariff refunds at this time (newer filing 2026-05-06)
- Added Q1 2026 financial results: $11.8 million net revenues, 22.1% increase; $7.2 million gross profit, 19.6% increase; 61.5% gross margin (newer filing 2026-05-06)
- Added detailed revenue breakdown table for Q1 2026 vs Q1 2025 showing Domestic Core $7.7M (11.7% growth), International Core $3.3M (35.2% growth), Pharma Services $0.7M (166.0% growth) (newer filing 2026-05-06)
- Removed:
- Removed reference to third quarter 2025 results: $10.4 million net revenues, 27.2% increase (older filing 2025-11-12)
- Removed reference to third quarter 2025 gross profit of $6.3 million, 20.8% increase; 60.2% gross margin (older filing 2025-11-12)
- Removed reference to third quarter 2025 operating expenses of $7.1 million (older filing 2025-11-12)
- Removed statement about tariff-related charges of $0.1 million incurred during third quarter 2025 (older filing 2025-11-12)
- Removed expectation that tariff-related charges would have less than 100 basis points gross margin impact on annualized basis (older filing 2025-11-12)
- Removed detailed revenue table for Q3 2025 vs Q3 2024 showing Domestic Core decline of 5.0%, International Core increase of 229.6% (older filing 2025-11-12)
- Removed reference to 'KORU' as alternate company identifier in opening section (newer filing uses only 'KORU Medical') (newer filing 2026-05-06)
- Reworded:
- Changed reference year in forward-looking statements from 'Annual Report on Form 10-K for the year ended December 31, 2024 and Quarterly Report for the quarter ended March 31, 2025' to 'Annual Report on Form 10-K for the year ended December 31, 2025' (newer filing 2026-05-06)
- Changed forward-looking statement qualifier from 'introduction of competitive products' to 'introduction and adoption of competitive products' (newer filing 2026-05-06)
- Removed phrase 'and impact of tariff-related charges' from forward-looking statements regarding additional financing (older filing 2025-11-12 included this; newer filing 2026-05-06 removed it)
- Notes:
- The newer filing text appears truncated at 'as compared to $6.0 m' in the Gross Profit section, limiting full comparison of that section
- The older filing text also appears truncated at the end regarding pharma services discussion, limiting complete comparison of final sections
Risk Factors
The two filings could not be meaningfully compared for this section.
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
2 open-market purchases and 0 open-market sales by insiders in the last 90 days.
- Last 90 days2 buys ($49275) · 0 sells — 1 buying insider
- Last 180 days8 buys ($2M) · 0 sells — 5 buying insiders
Cluster buying: 5 different insiders reported open-market purchases (SEC code P) of KRMD within a 30-day window between 2026-05-14 and 2026-06-11. Disclosed Form 4 activity, not a prediction of performance or a buy signal.
Activity heuristic: net buying (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-06-11. As of 2026-08-24.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about KRMD's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
5 institutional 13F filers reported holding KRMD as of 2026-03-31 (quarter-end position, filed within 45 days).
- Distinct 13F filers 5
- Reported shares held 3,140,147
- Reported value $13,565,434
reported quarterly holdings change (2025-12-31 → 2026-03-31): 1 new, 2 increased, 2 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Short interest (FINRA)
KRMD had 800,754 shares of reported short interest as of the 2026-07-31 FINRA settlement date (delayed, bi-monthly; not real-time).
KRMD had 1.73% of its shares outstanding sold short as of the 2026-07-31 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 5.45 days to cover at the same settlement.
- Reported short interest (shares) 800,754
- Short interest (% of shares outstanding) 1.73%
- Prior settlement (shares) 807,208
- Reported change -0.8%
- Days to cover (reported) 5.45
Reported to FINRA as of the 2026-07-31 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Becton Dickinson (BDX)
- Smiths Medical
- Tandem Diabetes Care (TNDM)
- Baxter International (BAX)
- Medtronic (MDT)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare KRMD vs…
Frequently asked questions
What does KORU MEDICAL SYSTEMS INC (KRMD) do?
Koru Medical develops and manufactures large-volume subcutaneous infusion systems, primarily the FREEDOM Infusion Systems (including syringe drivers, tubing, and needle sets), for drug delivery governed by FDA regulations and international quality standards. The company generates revenue from three streams: domestic and international core product sales of infusion devices for subcutaneous drugs (primarily immunoglobulin treatment for Primary Immunodeficiency Diseases and CIDP), and pharma…
What sector is KORU MEDICAL SYSTEMS INC (KRMD) in?
KORU MEDICAL SYSTEMS INC (KRMD) is classified in the Health Care sector. Its industry is Subcutaneous drug delivery and infusion systems. It trades on NASDAQ.
Who are KORU MEDICAL SYSTEMS INC's (KRMD) competitors?
Notable peers of KORU MEDICAL SYSTEMS INC (KRMD) include Becton Dickinson, Smiths Medical, Tandem Diabetes Care, Baxter International and Medtronic. This peer set is informational only — not financial advice.
Is KORU MEDICAL SYSTEMS INC (KRMD) overbought or oversold right now?
KORU MEDICAL SYSTEMS INC (KRMD) is currently in oversold territory (its 14-day RSI is 29, below 30) (as of 2026-08-21). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on KRMD come from?
Fundamentals and prices come from market data, as of 2026-08-24; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.